Tactile Systems Technology PE ratio TCMD
Share price divided by earnings per share over the last twelve months, since 2017.
- Today, Oct 23, 2026
- 21.9×
- 9-year median
- 62.9×
- Against its 9-year history
- 25th
- percentile: 0 is its lowest day, 100 its highest
- 9-year range
- 9.4× to 468×
- Peer median
- 28.3×
Tactile Systems Technology's PE ratio is 21.9× as of Oct 23, 2026: a share price of $23.64 against $1.08 of earnings per share over the last twelve months.
That is below its 9-year median of 62.9×, lower than on 75% of days in the last 9 years.
Over that time it ranged from 9.4× in Jul 2024 to 468× in Sep 2023.
The median for 10 medical instruments and supplies stocks of a similar size is 28.3×.
PE ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 21.9× | 20.3× | 39.6× |
| 2025 | 38.5× | 14.3× | 38.5× |
| 2024 | 26.5× | 9.4× | 30.1× |
| 2023 | 13.2× | 9.9× | 468× |
| 2022 | 37.2× | 37.2× | 45.0× |
| 2021 | 47.6× | 47.5× | 73.8× |
| 2020 | 100.0× | 55.4× | 152× |
| 2019 | 149× | 99.4× | 219× |
| 2018 | 129× | 90.5× | 222× |
| 2017 | 93.5× | 81.4× | 344× |
Against its peers
Companies in Medical - Instruments & Supplies nearest Tactile Systems Technology's size, closest first, today.
| Company | PE ratio |
|---|---|
| TCMDTactile Systems Technology | 21.9× |
| MDXGMimedx | 97.8× |
| MOVMovado | 17.5× |
| EMBCEmbecta | 4.6× |
| INFUInfuSystem | 34.0× |
| IRMDIradimed | 47.9× |
| STAAStaar Surgical | 323× |
| UTMDUtah Medical Products | 22.6× |
| BVSBioventus | 19.4× |
| CDRECadre | 37.0× |
| PDEXPro DEX | 15.1× |
| Peer median | 28.3× |
Where Tactile Systems Technology ranks
What the PE ratio tells you
Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.
Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.
More on Tactile Systems Technology
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.